Antipsychotic-induced weight gain and therapeutic response: A differential association

Journal of Clinical Psychopharmacology

Volumn 22, Issue 3, 2002, Pages 244-251

  Czobor, Pál ^a   Volavka, Jan ^a   Sheitman, Brian ^a   Lindenmayer, Jean Pierre ^a   Citrome, Leslie ^a   McEvoy, Joseph ^a   Cooper, Thomas B ^a   Chakos, Miranda ^a   Lieberman, Jeffrey A ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0036115924     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200206000-00003     Document Type: Article

References (45)

1. Body weight gain induced by antipsychotic drugs: Mechanisms and management
2. Antipsychotic-induced weight gain: A comprehensive research synthesis
3. Clozapine and weight gain
4. Novel antipsychotics: Comparison of weight gain liabilities
5. Atypical antipsychotics and weight gain: A systematic review
6. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
7. Differential effect of clozapine on weight: A controlled study
8. Clozapine-induced weight gain: Prevalence and clinical relevance
9. Therapeutic drug monitoring of olanzapine
10. Weight gain and clozapine
11. Olanzapine: Weight gain and therapeutic efficacy
12. Weight gain and response to olanzapine treatment in schizophrenia
13. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone
14. Weight change and atypical antipsychotic treatment in patients with schizophrenia
15. The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation
16. Nosie-30: History and current status of its use in pharmacopsychiatric research
17. Weight gain: Side effect of atypical neuroleptics?
18. Weight gain associated with antipsychotic drugs
19. Weight gain associated with neuroleptic medication: A review
20. Weight changes in relation to the characteristics of patients on chlorpromazine
21. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities
22. Brain dopamine and obesity
23. High levels of dopamine d2 receptor occupancy with low-dose haloperidol treatment: A PET study
24. Serotonin receptor subtypes: Possible roles and implications in antipsychotic drug action
25. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
26. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
27. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons
28. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience?
29. Effects of phentermine on striatal dopamine and serotonin release in conscious rats: In vivo microdialysis study
30. Mesolimbic dopaminergic system activity as a function of food reward: A microdialysis study
31. Genetic variants of the human obesity (OB) gene: Association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene
32. The mechanism of action of novel antipsychotic drugs
33. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
34. Neurochemical mechanism of action of anorectic drugs
35. Serotonin may play a role in the anorexia induced by amphetamine injections into the lateral hypothalamus
36. The concentrations of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution
37. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity
38. The role of serotonin in schizophrenia
39. Body weight and leptin plasma levels during treatment with antipsychotic drugs
40. Recent advances in basic obesity research
41. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks
42. Weight gain from novel antipsychotic drugs: Need for action
43. H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients
44. Weight gain and antipsychotic medication
45. Weight gain associated with use of psychotropic medications